Connect with us


Geman Biotech Stocks: Mologen (MGNK) goes insolvent while MorphoSys (MOR) strengthens its position

German biotech stocks are facing some significant challenges. The U.S. President Trump’s recent statements that a China deal will only be possible after the November 2020 elections has rattled some investors. Mologen’s shares fell by 75% on December 4, and are currently trading at $0.22 (€0.197). The Dow Jones Index climbed by 0.7% to 27,701 points, the NASDAQ by 0.6% to 8,572 points.



This picture show a screen displaying biotech information.

It’s been a turbulent time in the global stock markets. Continuing uncertainty surrounding the American-Chinese trade war and slowdown in Europe has caused tremors in the German Biotech markets generally. Standouts include Mologen (MGNK) which has gone insolvent and MorphoSys (MOR) has strengthened their position significantly. 

The DAX rose by 1.2% to 13,146 points, supported by Bayer, Fresenius, and Linde. The only losers are Vonovia, Wirecard, and Merck. The MDAX rose by 1.2% to 27,220 points and the TecDAX gained 1.2% to 3,041 points, supported by Siltronic, Drägerwerk, and S&T. New Work and Qiagen are slightly under pressure.

Stay informed about the latest biotech advances with Born2Invest. Our companion app includes news updates of finance headlines from finance and investing in cannabis, Africa, fin-tech, and more.

The Chinese American trade war has also been causing jitters amongst investors. According to a report by Bloomberg, negotiators from both countries have approached each other on the issue of the withdrawal of trade tariffs. At the same time, the U.S. President Trump’s recent statements that a dea with China will only be possible after the November 2020 elections remains in the minds of investors.

Markit analysts presented the latest purchasing managers’ indices for the European services sector in November. The index rose by 0.4 to 51.9 points. A decline was recorded in Italy and France. In the U.S., the corresponding ISM index fell by 0.8 to 53.9 points.

The Dow Jones Index climbed by 0.7% to 27,701 points, the NASDAQ by 0.6% to 8,572 points.

Mologen’s biotech shares fell by 75% and are currently trading at $0.22 (€0.197). The company filed for insolvency in Berlin on December 4.

Biotest lost 4.3% to $22.24 (€20.05), Qiagen lost 0.8% to $42.18 (€38.03) and BioFrontera lost 0.2% to $5 (€4.51).

On the other hand, MorphoSys improved by 3.1% to $127.35 (€114.80). Vita34 increased by 2.3% to $14.98 (€13.50), Evotec increased by 1.9% to $22.36 (€20.16) and 4SC by 1.4% to $2.48 (€2.24). BB Biotech and MagForce continue to grow.

On Wall Street, the NASDAQ Biotechnology Index rose by 0.3% to 3,756 points.

Arrowhead Pharmaceuticals are under pressure, losing 8.6% to $62.79, while Sarepta Therapeutics is down 1.2% to $110.00.

On the other hand, there are Gilead Sciences papers, which improved by 1.4% to $66.96. The paper price of Gilead Sciences was 1.9% lower than in the previous year. Vertex Pharmaceuticals increased by 0.8% to $222.99, Allergan by 0.6 percent% to $186.17 and Amgen increased by 0.6% to $234.13.

Biotech stocks continue to offer investors high-return opportunities. Again and again, small companies with new therapeutic approaches and ideas are taken over by industry leaders simply because they have to continuously expand their sales base. Not only the U.S. market is regarded as extremely important, but also, to an increasing extent, the Chinese market.


(Featured image by Stephen Dawson via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in shareribs, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Philip Gregg is a tech biz writer, with a keen understanding of blockchain technology, Internet of Things, and cloud services. He also serves as chief consultant for an IT business in Washington and a cryptowallet startup in Tokyo. Philip holds an MBA in finance and has previously worked at a Silicon Valley company before striking out on his own. He is a dad to three German Shepherds and owns a sweet vintage Mustang he fondly calls Sadie.